In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Diego Ardigò, Executive Vice President, Global R&D at Chiesi, a biopharma company focused on respiratory health, rare diseases and specialty care.
Respiratory medicine presents unique drug development challenges because successful therapies depend not only on the drug itself, but also on the formulation and delivery device. As innovation continues across asthma and chronic obstructive pulmonary disease (COPD), developers must balance performance, usability, sustainability and continuity of care.
In this episode, Diego discusses how Chiesi approaches innovation in respiratory disease drug development and why developing inhaled therapies requires careful integration of drug formulation, device design and patient experience. He explains the scientific and practical considerations involved in creating therapies that patients can use effectively in everyday life.
The conversation also explores the growing focus on sustainability in respiratory care. Diego discusses how the industry can transition toward more environmentally sustainable inhaler options while maintaining treatment continuity for patients who are stable on their current therapies.
In addition, Diego discusses the role of inhaler technique, patient behavior and long-term treatment adherence in shaping R&D decisions.
Diego also explains why respiratory medicine offers valuable lessons for the broader pharmaceutical industry in balancing innovation, sustainability and patient-centered care.
Tune in to learn more about the future of asthma and COPD drug development and how respiratory medicine is evolving to meet both patient and sustainability goals.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a comment
JOIN LOGIN